2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase

Carbonic Anhydrase

Carbonate dehydratase

Carbonic Anhydrase

Related Products

PDF 0.73 MB

Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct carbonic anhydrase enzyme families (α-, β-, γ- δ-, ζ-, η-, θ- and ι- CAs) were described to date. Carbonic anhydrases are involved in numerous physiological and pathological processes. Many of them are important therapeutic targets with the potential to be inhibited to treat a range of disorders including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.

The carbonic anhydrase reaction is involved in many physiological and pathological processes, including respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs; pH and CO2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis); bone resorption; calcification; and tumorigenicity. α-CAs are Zn2+ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa, and plants. Sixteen mammalian α-CA isoforms are known to be involved in many diseases such as glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc.

Carbonic Anhydrase Isoform Specific Products:

Carbonic Anhydrase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147986
    hCA I-IN-2
    		Inhibitor
    hCA I-IN-2 (Compound 6d) is a selective human carbonic anhydrase I (hCA I) inhibitor with Ki values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively.
    hCA I-IN-2
  • HY-178017
    BChE/hCA II-IN-1
    		Inhibitor
    BChE/hCA II-IN-1 (Compound 20) is a dual-functional inhibitor of Butyrylcholinesterase (BChE) and human carbonic anhydrase II (hCA II) with IC50s of 76.50 and 10.69  μM for BChE and hCA II, respectively. BChE/hCA II-IN-1 can be used for neurodegenerative diseases like Alzheimer's and glaucoma research.
    BChE/hCA II-IN-1
  • HY-B0122A
    Topiramate lithium
    		Inhibitor
    Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
    Topiramate lithium
  • HY-155522
    WES-1
    		Inhibitor
    WES-1 (Compound 8g) is an inhibitor of carbonic anhydrase IX (Ki: 55.9 μM). WES-1 has broad spectrum anti-proliferative activity against the cancer cells, such as leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI–H460), colon cancer (HCT 116 and HCT-15) and melanoma (LOX IMVI) cell lines.
    WES-1
  • HY-150695
    hCAIX/XII-IN-5
    		Inhibitor
    hCAIX/XII-IN-5 (Coumarin 9a) a carbonic anhydrase (CA) inhibitor, and exhibits excellent hCA IX/XII selectivity (Ki=93.9 and 85.7 nM, respectively) over hCA I and hCA II. hCAIX/XII-IN-5 shows anti-proliferative activities to cancer cells. hCAIX/XII-IN-5 can delay cell cycle and induce apoptosis.
    hCAIX/XII-IN-5
  • HY-168124
    Carbonic anhydrase inhibitor 26
    		Inhibitor
    Carbonic anhydrase inhibitor 26 (compund 6T) is a carbonic anhydrase II inhibitor with IC50 of 9.10 ± 0.26 μM.
    Carbonic anhydrase inhibitor 26
  • HY-178030
    CAXII-IN-3
    		Inhibitor
    CAXII-IN-3 is an effective carbonic anhydrase (CA XII) inhibitor with a Ki of 53 nM. CAXII-IN-3 exhibits selective inhibition against multiple human CA subtypes with Kis of 5.3 μM, 75 nM, 1.9 μM, > 10 μM against CA I, CA II, CA IV and CA IX. CAXII-IN-3 mainly inhibits CA II and XII, and reduces aqueous humor production. CAXII-IN-3 exhibits β3-AR agonistic activity, can dilate retinal blood vessels, and improve optic nerve perfusion. CAXII-IN-3 can be used in the research of ocular disorders such as glaucoma.
    CAXII-IN-3
  • HY-155271
    hCAXII-IN-7
    		Inhibitor
    hCAXII-IN-7 (compound 6e) is a hCA XII inhibitor. hCAXII-IN-7 has BBB permeability. hCAXII-IN-7 induces 786-0, SF-539 and HS 578 T cells apoptotic.
    hCAXII-IN-7
  • HY-161174
    Carbonic anhydrase inhibitor 17
    		Inhibitor
    Carbonic anhydrase inhibitor 17 (compound 7c) ,pyridazine-tethered sulfonamide, is a carbonic anhydrase II inhibitor with IC50 of 0.63 nM.
    Carbonic anhydrase inhibitor 17
  • HY-150573
    CDK2-IN-12
    		Inhibitor
    CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity.
    CDK2-IN-12
  • HY-175239
    CAII/CAXII-IN-1
    		Inhibitor
    CAII/CAXII-IN-1 (compound 8d) is a CAII/CAXII inhibitor with IC50 values of 0.38 µM and 0.61 µM for CAII and CAXII, respectively.
    CAII/CAXII-IN-1
  • HY-B0124S3
    Zonisamide-15N,d4
    Zonisamide-15N,d4 is the 15N- and deuterium labeled Zonisamide (HY-B0124). Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
    Zonisamide-<sup>15</sup>N,d<sub>4</sub>
  • HY-155760
    hCA/VEGFR-2-IN-3
    		Inhibitor
    hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC50=358 nM), has high binding activity to hCAs with Ki of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells.
    hCA/VEGFR-2-IN-3
  • HY-161522
    α-Glucosidase-IN-63
    		Inhibitor
    α-Glucosidase-IN-63 (Compound 4d) is an inhibitor of α-Glucosidase (IC50=0.44 μM). α-Glucosidase-IN-63 inhibits hCA II with an activity of Ki= 7.0 nM. α-Glucosidase-IN-63 is orally effective..
    α-Glucosidase-IN-63
  • HY-120677
    AHR-15010
    		Inhibitor
    AHR-15010 is an oral active carbonic anhydrase inhibitor with the IC50 of 0.13 μM. AHR-15010 shows anti-arthritic activity and can be used for study of arthritis .
    AHR-15010
  • HY-156013
    CA inhibitor 2
    		Inhibitor
    CA inhibitor 2 (Compound 4H) is a carbonic anhydrase inhibitor (IC50: 0.033 μM).
    CA inhibitor 2
  • HY-147828
    hCAIX-IN-11
    		Inhibitor
    hCAIX-IN-11 (Compound 5d) is a selective carbonic anhydrase IX and XII inhibitor with Ki s of 32.7 and 623.5 nM for hCA IX and hCA XII, respectively.  hCA IX and hCA XII are transmembrane isoforms which have been characterized as biomarkers for several types of tumors. The hCA XII assists in maintenance of acid-base homoeostasis in normal as well as tumor cells.
    hCAIX-IN-11
  • HY-151472
    hCAIX/XII-IN-6
    		Inhibitor
    hCAIX/XII-IN-6 is an orally active carbonic anhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA).
    hCAIX/XII-IN-6
  • HY-183590
    CAIX/XII-IN-17
    		Inhibitor
    CAIX/XII-IN-17 is a selective human carbonic anhydrase IX/XII (CA IX/XII) inhibitor with Ki values of 25.1 nM (hCA IX) and 35.2 nM (hCA XII). CAIX/XII-IN-17 induces apoptosis in pancreatic cancer cells. CAIX/XII-IN-17 can be used for the research of breast cancer, pancreatic cancer.
    CAIX/XII-IN-17
  • HY-147663
    hCAIX-IN-6
    Compounds 6b and 14g showed significant inhibitory effect on tumor related subtype HCA IX with low nanomolar potency, while 6k was effective on HCA XII. Compounds 6b, 14g and 6k can be considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.
    hCAIX-IN-6
Cat. No. Product Name / Synonyms Species Source
Carbonic Anhydrase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.